Clinical Trial Update: A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safe and effective dose of CHF10067 (Zampilimab) for idiopathic pulmonary fibrosis, sponsored by Chiesi Farmaceutici.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Zampilimab (Zampilimab)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: NOT_YET_RECRUITING